<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-03T22:16:30Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10256/27653" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10256/27653</identifier><datestamp>2026-03-07T07:57:50Z</datestamp><setSpec>com_2072_452955</setSpec><setSpec>com_2072_2054</setSpec><setSpec>col_2072_452958</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Intracranial self-stimulation reverses impaired spatial learning and regulates serum microRNA levels in a streptozotocin-induced rat model of Alzheimer disease</dc:title>
   <dc:creator>Riberas Sánchez, Andrea</dc:creator>
   <dc:creator>Puig Parnau, Irene</dc:creator>
   <dc:creator>Vila-Solés, Laia</dc:creator>
   <dc:creator>García-Brito, Soleil</dc:creator>
   <dc:creator>Aldavert Vera, Laura</dc:creator>
   <dc:creator>Segura Torres, Pilar</dc:creator>
   <dc:creator>Huguet i Blanco, Gemma</dc:creator>
   <dc:creator>Kádár García, Elisabeth</dc:creator>
   <dc:contributor>Agencia Estatal de Investigación</dc:contributor>
   <dc:subject>Neurociències</dc:subject>
   <dc:subject>Neurosciences</dc:subject>
   <dc:subject>Alzheimer, Malaltia d'</dc:subject>
   <dc:subject>Alzheimer's disease</dc:subject>
   <dc:subject>Cervell -- Estimulació</dc:subject>
   <dc:subject>Brain stimulation</dc:subject>
   <dc:description>Background: The assessment of deep brain stimulation (DBS) as a therapeutic alternative for treating Alzheimer disease (AD) is on-going. We aimed to determine the effects of intracranial self-stimulation at the medial forebrain bundle (MFB-ICSS) on spatial memory, neurodegeneration, and serum expression of microRNAs (miRNAs) in a rat model of sporadic AD created by injection of streptozotocin. We hypothesized that MFB-ICSS would reverse the behavioural effects of streptozotocin and modulate hippocampal neuronal density and serum levels of the miRNAs. Methods: We performed Morris water maze and light-dark transition tests. Levels of various proteins, specifically amyloid-β precurser protein (APP), phosphorylated tau protein (pTAU), and sirtuin 1 (SIRT1), and neurodegeneration were analyzed by Western blot and Nissl staining, respectively. Serum miRNA expression was measured by reverse transcription polymerase chain reaction. Results: Male rats that received streptozotocin had increased hippocampal levels of pTAU S202/T205, APP, and SIRT1 proteins; increased neurodegeneration in the CA1, dentate gyrus (DG), and dorsal tenia tecta; and worse performance in the Morris water maze task. No differences were observed in miRNAs, except for miR-181c and miR-let-7b. After MFB-ICSS, neuronal density in the CA1 and DG regions and levels of miR-181c in streptozotocin-treated and control rats were similar. Rats that received streptozotocin and underwent MFB-ICSS also showed lower levels of miR-let-7b and better spatial learning than rats that received streptozotocin with-out MFB-ICSS. Limitations: The reversal by MFB-ICSS of deficits induced by streptozotocin was fairly modest. Conclusion: Spatial memory performance, hippocampal neurodegeneration, and serum levels of miR-let-7b and miR-181c were affected by MFB-ICSS under AD-like conditions. Our results validate the MFB as a potential target for DBS and lend support to the use of specific miRNAs as promising biomarkers of the effectiveness of DBS in combatting AD-associated cognitive deficits</dc:description>
   <dc:description>This work was supported by grants PID2020-117101RB-C21 and PDI2020-117101RB-C22 from the Ministerio de Ciencia eInnovación, Spain. Andrea Riberas-Sánchez received a predoctoralfellowship from the Universitat de Girona (IFUdG2022/63)</dc:description>
   <dc:date>2024-03-15</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:type>peer-reviewed</dc:type>
   <dc:identifier>http://hdl.handle.net/10256/27653</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1503/jpn.230066</dc:relation>
   <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1180-4882</dc:relation>
   <dc:relation>info:eu-repo/semantics/altIdentifier/eissn/1488-2434</dc:relation>
   <dc:relation>PID2020-117101RB-C22</dc:relation>
   <dc:relation>info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117101RB-C22/ES/ESTIMULACION  ELECTRICA REFORZANTE COMO TRATAMIENTO PROTECTOR DEL DETERIORO COGNITIVO EN ENFERMEDAD DE ALZHEIMER: BIOMARCADORES Y VERIFICACION EN MUESTRAS DE PACIENTES/</dc:relation>
   <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Canadian Medical Association</dc:publisher>
   <dc:source>Journal of Psychiatry and Neuroscience, 2024, vol. 49, núm. 2, p. E96-E108</dc:source>
   <dc:source>Articles publicats (D-B)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>